Investment bank issues rating upgrades for UCB, while an analyst firm raises the outlook on the company's stock.
4 reports, 1 independent
Updated Sep 11
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Investment bank issues rating upgrades for UCB, while an analyst firm raises the outlook on the company's stock.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
UCB
biopharmaceutical company headquartered in Brussels, Belgium
-
Keefe, Bruyette & Woods
investment bank
Related events
- Keefe, Bruyette & Woods upgraded the stock rating for River City Bank to moderate buy, assuming coverage and setting outperform rating. The bank is headquartered in Sacramento.
- Keefe, Bruyette & Woods upgraded the price objective for HomeTrust Bancshares, Inc., coinciding with institutional investor acquisitions and a dividend announcement.
- Multiple financial firms, including Keefe, Bruyette & Woods, raised price targets for Marex Group plc Ordinary Shares.
- Keefe, Bruyette & Woods and Royal Bank of Canada lowered ratings and price objectives, with MarketBeat providing consensus data.
- Civita Bancshares, Inc. is receiving investment analysis and rating updates from the firm Keefe, Bruyette & Woods.